by Raynovich Rod | Oct 10, 2018 | Biopharmaceuticals, Macro
Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum...
by Raynovich Rod | Sep 4, 2018 | Biopharmaceuticals
Update: 10:10a Tesaro (TSRO) Soars 15% to $38, short covering or bargain hunters? News item: expansion of Zejula Combo Trial in NSCLC ========= Biotech Weakness in Large Caps Mid-Caps Have Continued Strength The overall market recovered from an early sell-off but...
by Raynovich Rod | Aug 31, 2018 | Biopharmaceuticals
9/4/18 Biotech Weakness -Profit Taking or Caution for September Swoon? 1 PM EDT FBT down 1.38%, IBB down 1.55%, XBI down 0.73% Biotech stocks were extremely weak as of mid-day trading. Large caps were unusually weak given that they should be less volatile: CELG down...
by Raynovich Rod | Aug 23, 2018 | 2023-24 Life Science Portfolios, Biopharmaceuticals, Clinical Diagnostics and Tools
8/24/18 After Close: Rally Continues with 10/11 Sectors Higher XLV finishes at all time high at $91.89 FED’s Powell Defends Gradual Interest Rate Policy despite Trump pressure Oil Surges 15 to $68.57 on supply concerns with Iran sanctions Major indices hit 52...
by Raynovich Rod | Jul 29, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 7/30 at close- -Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen: ACAD down 4.08%, ALNY down 7.37%,...
by Raynovich Rod | Jul 22, 2018 | Biopharmaceuticals
7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9% to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock...
by Raynovich Rod | Jun 30, 2018 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Biotech Bull Market: Up 25.39% Over 2 Years With High Volatility XBI Outperforms Up 12% YTD; FBT is Comparable, IBB lags. Three Funds did well in H1 2018 (7-9%). Biotech stocks peaked in July 2015 and reached a bottom on 10/31/16 gradually clawing their way back to a...
by Raynovich Rod | Jun 21, 2018 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Momentous Biotech for June Update 6/28…A nice broad rally on Friday included the large cap biotechs with the IBB up 1.73% to $109.82. Even Celgene (CELG) found buyers up 3.6% flirting with the $80 level. The big winner was Vertex (VRTX) up 15.16% to the $170...
by Raynovich Rod | Jun 13, 2018 | Biopharmaceuticals
Updated 6/18 pre-market Biotech Update for Week Ending 6/15 A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of...
by Raynovich Rod | Jun 3, 2018 | Biopharmaceuticals
6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%. Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news....